Compare DFIN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFIN | MIRM |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | 1800 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 4.2B |
| IPO Year | N/A | 2019 |
| Metric | DFIN | MIRM |
|---|---|---|
| Price | $46.31 | $78.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $63.50 | ★ $92.45 |
| AVG Volume (30 Days) | 267.6K | ★ 813.7K |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | ★ $750,800,000.00 | $471,794,000.00 |
| Revenue This Year | N/A | $53.78 |
| Revenue Next Year | $4.20 | $19.91 |
| P/E Ratio | $41.41 | ★ N/A |
| Revenue Growth | N/A | ★ 53.66 |
| 52 Week Low | $37.80 | $36.88 |
| 52 Week High | $69.93 | $82.58 |
| Indicator | DFIN | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 62.89 |
| Support Level | $45.72 | $63.23 |
| Resistance Level | $46.57 | $82.58 |
| Average True Range (ATR) | 1.17 | 3.74 |
| MACD | 0.12 | 1.62 |
| Stochastic Oscillator | 69.26 | 81.03 |
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.